Why Syphilis Serology & Treatment Navigator?
Decodes Algorithmic & Discordant Complexity
Seamlessly untangles both Traditional (RPR-first) and Reverse (EIA/CIA-first) screening pathways, resolving discordant treponemal results with automated TP-PA reflex tiebreaker logic and biological false-positive discrimination.
Visual Titer Dynamics & Reinfection Triage
Features an interactive serial dilution ladder that operationalizes the CDC 4-fold (2-dilution) rule, distinguishing true treatment success and serofast states from reinfection, serological relapse, or prozone phenomena without manual calculation errors.
CDC 2021 Safety Hard-Stops & EHR Export
Enforces critical clinical mandates—including mandatory penicillin desensitization during pregnancy, strict 7-day adherence intervals for late latent syphilis, and lumbar puncture criteria for neurosyphilis—while generating instant EHR dotphrases and consultation notes.
Clinical Workflow: 5-Module Architecture
Module 1: Baseline Screen & Serological Testing Profile
- Critical Host Safeguards: Captures pregnancy status, penicillin allergy verification, and HIV status (prompting q3mo vs. q6mo serological monitoring cadences).
- Algorithm Dual-Path Engine: Supports automated Reverse Screening (EIA/CIA reflexed to RPR, with second treponemal TP-PA tiebreaker) and Traditional Screening (quantitative RPR reflexed to confirmatory treponemal assay).
- Interactive Serial Dilution Ladder: Real-time quantitative titer tracking (from Non-Reactive to 1:2048) with step-by-step visual mapping of 2-fold (1-step) and 4-fold (2-step) titer movements.
- Prior Treatment Comparison: Directly evaluates current quantitative titers against documented post-treatment baselines to establish treatment response, serofast state, or re-infection.
Module 2: Clinical Staging & Manifestations Engine
- Stage Differentiation: Diagnostic criteria for Primary (painless chancre), Secondary (diffuse rash including palms/soles, condyloma lata, lymphadenopathy), Early Latent (<1 year acquisition), and Late Latent/Unknown Duration.
- Neuro/Ocular/Otosyphilis Triage: Evaluates cranial neuropathies, visual changes, uveitis, sensorineural hearing loss, and altered mental status triggering mandatory cerebrospinal fluid (CSF) evaluation.
- Early Latent Documentation Validator: Enforces CDC criteria for <1 year duration (prior negative serology within 12 months, documented 4-fold rise, unequivocal primary/secondary symptoms, or exposure to confirmed early syphilis).
Module 3: CDC Treatment Protocol & Formulation Guidance
- Guideline Regimen Selection: Automatically specifies first-line Benzathine Penicillin G (Bicillin L-A) dosing (2.4 MU IM single dose vs. 7.2 MU total across 3 weekly doses of 2.4 MU).
- Critical Formulation Warning: Clear safety hard-stop distinguishing Bicillin L-A from Bicillin C-R (which contains procaine penicillin and is contraindicated for syphilis).
- Alternative Regimen Protocol: Outlines non-pregnant penicillin-allergic alternatives (Doxycycline 100 mg BID for 14 or 28 days; Ceftriaxone 1g daily) with strict warnings against macrolide/azithromycin resistance.
- Pregnancy Safety Directives: Strict alert barring non-penicillin alternatives during pregnancy and mandating inpatient penicillin desensitization.
Module 4: EHR Documentation & Clinical Decision HUD
- Real-Time Decision HUD: Persistent clinical heads-up display reflecting current staging, safety flags, and exact target prescription directives.
- Structured EHR Dotphrase Generator: Single-click export of clinical documentation (.SYPHILISNOTE) capturing baseline serologies, staging rationale, prescribed therapy, and follow-up intervals.
- Jarisch-Herxheimer Counseling: Generates standardized anticipatory guidance regarding self-limiting febrile inflammatory reactions within 24 hours of starting therapy.
Module 5: Post-Treatment Monitoring & Surveillance Cadence
- Serological Surveillance Intervals: Formulates specific repeat non-treponemal titer schedules (6 and 12 months for immunocompetent early syphilis; 3, 6, 9, 12, and 24 months for persons with HIV or late latent stages).
- 4-Fold Drop Interpretation: Validates successful cure criteria (e.g., titer decline from 1:32 to ≤1:8) and delineates protocols for non-responders or serofast titers.
- Partner Notification & Expedited Presumptive Therapy: Establishes lookback windows (90 days plus duration of symptoms for primary, 6 months for secondary, 1 year for early latent) for sexual contact testing and presumptive treatment.
How to Use the Syphilis Serology & Treatment Navigator in Practice
- Input Patient Safeguards & Baseline Profile: Select pregnancy status, verify penicillin allergy details, record HIV status, and choose either the Traditional or Reverse screening algorithm.
- Log Serologies & Dilution Titers: Enter qualitative treponemal and non-treponemal results, then select the quantitative dilution titer (e.g., 1:16) using the interactive serial dilution ladder.
- Compare Prior Baselines & Confirm Clinical Staging: Document previous syphilis treatment history to evaluate 4-fold titer dynamics, and record presenting signs (chancres, rash, condyloma lata) or neurological symptoms to establish disease staging.
- Review the Clinical Decision HUD: Confirm the CDC-recommended medication regimen, verifying correct Bicillin L-A dosing, interval spacing rules, and desensitization requirements.
- Export Clinical Dotphrases & Set Monitoring Dates: Advance to the EHR module to copy the structured note into your medical record and establish follow-up titer dates aligned with CDC surveillance schedules.
